F. David Tingley

2.8k citations

19 papers · 1.4k indexed · h-index 13

Molecular Biology top 10%
Cellular and Molecular Neuroscience top 5%
Behavioral Neuroscience top 1%
Physiology top 10%
Pharmacology top 5%

Co-authors: David W. Schulz Robert S. Mansbach Lorraine A. Lebel Steven B. Sands Hans Rollema Michael L. Corman P A SeymourYi Lu
Topics: Receptor Mechanisms and Signaling (6 papers)Neuroscience and Neuropharmacology Research (4 papers)Nicotinic Acetylcholine Receptors Study (4 papers)
Cited by: Behavioral Neuroscience Biological Psychiatry Cellular and Molecular Neuroscience
Journals: Proceedings of the National Academy of Sciences Brain Research Journal of Medicinal Chemistry
Partner nations: United States United Kingdom

In The Last Decade

F. David Tingley

19 papers receiving 1.3k citations

Peers

Countries citing papers authored by F. David Tingley

Since Specialization

Citations

This map shows the geographic impact of F. David Tingley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. David Tingley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. David Tingley more than expected).

Fields of papers citing papers by F. David Tingley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. David Tingley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. David Tingley. The network helps show where F. David Tingley may publish in the future.

Co-authorship network of co-authors of F. David Tingley

This figure shows the co-authorship network connecting the top 25 collaborators of F. David Tingley. A scholar is included among the top collaborators of F. David Tingley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. David Tingley. F. David Tingley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	P1‐114: MEASUREMENT OF ENDOGENOUS MOUSE TAU IN CEREBROSPINAL FLUID FROM AGED PDAPP MICE FOLLOWING TREATMENT WITH AB‐LOWERING COMPOUNDS 2018 ·Alzheimer s & Dementia ·(unknown),Theresa A. Day,Justin T. Hole,F. David Tingley,Patricia A. Gonzalez‐DeWhitt,Dustin J. Mergott,David L. McKinzie,Ronald B. DeMattos,Mansuo L. Hayashi,David Riddell	2
2	P3‐075: The Relationship of TAU Pathology and Extracellular TAU in the Brains of TG4510 Mice 2016 ·Alzheimer s & Dementia ·Su Wu,(unknown),Eyassu Chernet,F. David Tingley,Theresa A. Day,Xiyun Chai,Kjell Svensson,Mansuo L. Hayashi	1
3	Application of neurophysiological biomarkers for Huntington's disease: Evaluating a phosphodiesterase 9A inhibitor 2014 ·Experimental Neurology ·Dávid Nagy,F. David Tingley,Milan Stoiljković,Mihály Hajós	16
4	Development and validation of a sample stabilization strategy and a UPLC–MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF) 2011 ·Journal of Chromatography B ·Yanhua Zhang,F. David Tingley,Elaine Tseng,(unknown),Xin Yang,Elizabeth Groeber,Jianhua Liu,Wenlin Li,Christopher J. Schmidt,Rick C. Steenwyk	30
5	The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter 2009 ·Bioorganic & Medicinal Chemistry Letters ·John Lowe,Xinjun Hou,Christopher Schmidt,F. David Tingley,(unknown),(unknown),Shari L. DeNinno,Mark A. Sanner,Karen Ward,Lorraine A. Lebel,(unknown),James J. Valentine	25
6	An octahydro-cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter 2009 ·Bioorganic & Medicinal Chemistry Letters ·John Lowe,Shari L. DeNinno,Susan E. Drozda,Christopher J. Schmidt,Karen Ward,F. David Tingley,Mark A. Sanner,(unknown),James J. Valentine	8
7	P2‐241: PDE9A‐mediated regulation of cGMP: Developing a biomarker for a novel therapy for Alzheimer's disease 2009 ·Alzheimer s & Dementia ·Christopher J. Schmidt,John F. Harms,F. David Tingley,Kari Schmidt,Wendy O. Adamowicz,(unknown),Robin J. Kleiman,Chris Barry,Timothy Coskran,Sharon O'Neill,Diane Stephenson,Frank S. Menniti	7
8	Low efficacy partial agonists of the α4β2 nicotinic acetylcholine receptor (nAChR). Does functional efficacy govern in vivo response? 2009 ·Biochemical Pharmacology ·Jotham W. Coe,Paige R. Brooks,Michael Wirtz,Michael G. Vetelino,Eric P. Arnold,Steven B. Sands,Thomas I. Davis,Lorraine A. Lebel,Carol B. Fox,Alka Shrikhande,Robert S. Mansbach,Leslie K. Chambers,(unknown),David W. Schulz,F. David Tingley,Brian T. O’Neill,Hans Rollema	1
9	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia 2008 ·Journal of Pharmacology and Experimental Therapeutics ·C J Schmidt,Douglas S. Chapin,(unknown),Michael L. Corman,Mihály Hajós,John F. Harms,William E. Hoffman,Lorraine A. Lebel,Sheryl A. McCarthy,(unknown),(unknown),Mark J. Majchrzak,Andres D. Ramirez,Karl T. Schmidt,P A Seymour,Judith A. Siuciak,F. David Tingley,Robert D. Williams,Patrick R. Verhoest,Frank S. Menniti	238
10	Synthesis and SAR of 2-Aryloxy-4-alkoxy-pyridines as Potent Orally Active Corticotropin-Releasing Factor 1 Receptor Antagonists 2008 ·Journal of Medicinal Chemistry ·Yuhpyng L. Chen,John P. Braselton,(unknown),Randall J. Gallaschun,Robert S. Mansbach,Anne W. Schmidt,Thomas Seeger,Jeffrey Sprouse,F. David Tingley,(unknown),David W. Schulz	35
11	2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists 2008 ·Journal of Medicinal Chemistry ·Yuhpyng L. Chen,R. Scott Obach,John P. Braselton,Michael L. Corman,(unknown),(unknown),Randall J. Gallaschun,Robert S. Mansbach,Anne W. Schmidt,Jeffrey Sprouse,F. David Tingley,(unknown),David W. Schulz	52
12	Pharmacological Effects of Nicotine on Norepinephrine Metabolism in Rat Brown Adipose Tissue: Relevance to Nicotinic Therapies for Smoking Cessation 2008 ·Toxicologic Pathology ·Dominique Brees,Michael R. Elwell,F. David Tingley,Steven B. Sands,Amy Jakowski,A C Shen,Jenny Cai,Martin B. Finkelstein	9
13	The neurokinin‐1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model 2007 ·Journal of Veterinary Pharmacology and Therapeutics ·(unknown),F. David Tingley,Richard Schneider,M. Anne Hickman	26
14	Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid 2006 ·Neuropharmacology ·Hans Rollema,Leslie K. Chambers,J.W. Coe,John R. Glowa,Raymond S Hurst,Lorraine A. Lebel,Yi Lu,Robert S. Mansbach,Robert J. Mather,(unknown),Steven B. Sands,Eric Schaeffer,David W. Schulz,F. David Tingley,Kathryn Williams	446
15	In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine 2005 ·Bioorganic & Medicinal Chemistry Letters ·Jotham W. Coe,Michael G. Vetelino,(unknown),Michael Wirtz,Paige R. Brooks,Eric P. Arnold,Lorraine A. Lebel,Carol B. Fox,Steven B. Sands,Thomas I. Davis,David W. Schulz,Hans Rollema,F. David Tingley,Brian T. O’Neill	49
16	3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation 2005 ·Bioorganic & Medicinal Chemistry Letters ·Jotham W. Coe,Paige R. Brooks,Michael Wirtz,(unknown),(unknown),Michael G. Vetelino,Eric P. Arnold,Lorraine A. Lebel,Carol B. Fox,F. David Tingley,David W. Schulz,Thomas I. Davis,Steven B. Sands,Robert S. Mansbach,Hans Rollema,Brian T. O’Neill	57
17	P-Glycoprotein Efflux at the Blood-Brain Barrier Mediates Differences in Brain Disposition and Pharmacodynamics between Two Structurally Related Neurokinin-1 Receptor Antagonists 2001 ·Journal of Pharmacology and Experimental Therapeutics ·Bill J. Smith,Angela C. Doran,Stafford McLean,F. David Tingley,Brian T. O’Neill,Shama Kajiji	27
18	CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. 1996 ·Proceedings of the National Academy of Sciences ·David W. Schulz,Robert S. Mansbach,Jeffrey Sprouse,John P. Braselton,J.L. Collins,Michael L. Corman,A. DUNAISKIS,(unknown),Anne W. Schmidt,Thomas Seeger,P A Seymour,F. David Tingley,(unknown),(unknown),James Heym	308
19	Evidence for clonidine presynaptically modulating amino acid release in the rostral ventral medulla: role in hypertension 1990 ·Brain Research ·F. David Tingley,Stephen P. Arnerić	32

About F. David Tingley

F. David Tingley is a scholar working on Behavioral Neuroscience, Biological Psychiatry and Cellular and Molecular Neuroscience, having authored 19 papers that have together received 1.4k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (6 papers), Neuroscience and Neuropharmacology Research (4 papers) and Nicotinic Acetylcholine Receptors Study (4 papers). The work is most often cited by research in Behavioral Neuroscience (327 citations), Biological Psychiatry (143 citations) and Cellular and Molecular Neuroscience (407 citations). F. David Tingley has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include David W. Schulz, Robert S. Mansbach, Lorraine A. Lebel, Steven B. Sands, Hans Rollema, Michael L. Corman, P A Seymour, Yi Lu, Eric Schaeffer and Robert J. Mather. Their work appears in journals such as Proceedings of the National Academy of Sciences, Brain Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact